贝达喹啉方案治疗耐药结核的疗效与心脏安全性:前瞻性队列研究
该研究在南非三省开展观察性队列研究,纳入195例耐利福平结核患者,其中40%为广泛耐药结核,97%联用氯法齐明。结果显示74%治愈或完成治疗,QTcF从基线至第6个月平均延长23.7毫秒,仅4例QTcF>500毫秒、19例ΔQTcF>60毫秒,严重QT延长不常见且无需永久停药。
要点
- 贝达喹啉方案治疗耐利福平结核治愈或完成治疗率达74%。
- QTcF从基线至第6个月平均延长23.7毫秒,严重QT延长不常见。
- 高龄与QT延长独立相关,老年患者建议密切监测QT间期。
核心结论
- 贝达喹啉方案治疗耐利福平结核疗效良好,严重QT延长不常见且无需永久停用贝达喹啉或氯法齐明。
研究设计与样本
- 研究为在南非3省开展的前瞻性观察性队列研究,纳入195例耐利福平结核患者。
- 患者在贝达喹啉治疗期间4个时间点接受三联心电图监测,随访至治疗结束或24个月。
主要发现
- 74%的参与者治愈或成功完成治疗,且 outcomes 不因HIV状态而异。
- QTcF从基线至第6个月平均增加23.7(标准差22.7)毫秒。
- 4例出现QTcF>500毫秒,19例出现ΔQTcF>60毫秒。
- 高龄与QT延长独立相关。
- 联用洛匹那韦-利托那韦者QT延长既不更常见也不更严重。
关键数值与推荐
- QT延长定义为经Fridericia法校正的QT间期(QTcF)>500毫秒或较基线绝对变化(ΔQTcF)>60毫秒。
临床怎么用
- 贝达喹啉方案可用于耐利福平结核治疗,严重QT延长不常见且无需永久停药。
- 老年患者建议密切监测QT间期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bedaquiline improves treatment outcomes in patients with rifampin-resistant (RR) tuberculosis but prolongs the QT interval and carries a black-box warning from the US Food and Drug Administration. The World Health Organization recommends that all patients with RR tuberculosis receive a regimen containing bedaquiline, yet a phase 3 clinical trial demonstrating its cardiac safety has not been published. METHODS: We conducted an observational cohort study of patients with RR tuberculosis from 3 provinces in South Africa who received regimens containing bedaquiline. We performed rigorous cardiac monitoring, which included obtaining electrocardiograms in triplicate at 4 time points during bedaquiline therapy. Participants were followed up until the end of therapy or 24 months. Outcomes included final tuberculosis treatment outcome and QT interval prolongation (QT prolongation), defined as any QT interval corrected by the Fridericia method (QTcF) >500 ms or an absolute change from baseline (ΔQTcF) >60 ms. RESULTS: We enrolled 195 eligible participants, of whom 40% had extensively drug-resistant tuberculosis. Most participants (97%) received concurrent clofazimine. Of the participants, 74% were cured or successfully completed treatment, and outcomes did not differ by human immunodeficiency virus status. QTcF continued to increase throughout bedaquiline therapy, with a mean increase (standard deviation) of 23.7 (22.7) ms from baseline to month 6. Four participants experienced a QTcF >500 ms and 19 experienced a ΔQTcF >60 ms. Older age was independently associated with QT prolongation. QT prolongation was neither more common nor more severe in participants receiving concurrent lopinavir-ritonavir. CONCLUSIONS: Severe QT prolongation was uncommon and did not require permanent discontinuation of either bedaquiline or clofazimine. Close monitoring of the QT interval may be advisable in older patients.
引用
- Brust JCM, Gandhi NR, Wasserman S, et al. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clin Infect Dis. 2021. PMID: 33882121. doi:10.1093/cid/ciab335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。